Synthesis, structure and antiaggregatory effects of some N-(4,5-dihydro- 1H-imidazol-2-yl)indoles

Farmaco

Volumn 55, Issue 1, 2000, Pages 56-64

  Saczewski, Franciszek ^a   Debowski, Tomasz ^a   Petrusewicz, Jacek ^a   Gdaniec, Maria ^b   Dabrowski, R Kamil ^a   Nowakowska, Emilia ^c  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c Regional Blood Bank   (Poland)

Author keywords

Antiaggregatory activities; N (4,5 Dihydro 1H imidazol 2 yl)indoles; Synthesis; X ray structure

Indexed keywords

ANTITHROMBOCYTIC AGENT; INDOLE DERIVATIVE; N (4,5 DIHYDRO 1H IMIDAZOL 2 YL)INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

CRYSTALLOGRAPHY, X-RAY; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PLATELET AGGREGATION INHIBITORS;

EID: 0034102508     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00123-8     Document Type: Article

References (25)

1. 2-adrenoreceptor suntypes. Annu. Rev. Pharmacol. Toxicol. 32:1993;241.
2. Hielbe J.P., Bondinell W.E., Ruffolo R.R. α- and β-adrenoreceptore: from the gene to the clinic. 1. Molecular biology and adrenereceptor subclassification. J. Med. Chem. 38:1995;3415.
3. Ruffolo R.R., Bondinell W.E., Hielbe J.P. α- and β-adrenoreceptore: from the gene to the clinic. 2. Structure-activity relationships and therepeutic applications. J. Med. Chem. 38:1995;3681.
4. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., Dillon M.P. Seeing through a glass darkly: casting light on imidazoline 1 sites. TiPS. 19:1998;381.
5. Hsu C.Y., Knapp D.R., Halushka P.V. The effects of α-adrenergic agents on human platelet aggregation. J. Pharmacol. Exp. Ther. 208:1979;366.
6. 2-adrenoreceptors primarily responsible for inducing human platelet aggregation. Nature. 227:1979;659.
7. Ahn C.H., Hamada A., Feller D.D. Alpha-adrenoreceptor-mediated actions of optical isomers and deoxy analogs of catecholimidazoline and norepinephrine in human platelets. Biochem. Pharmacol. 35:1986;4095.
8. 2-adrenoreceptor effects of substituted catecholimidazole and catecholimidazoline analogs in human platelets. J. Med. Chem. 33:1990;1138.
9. Saczewski F., Debowski T., Gdaniec M., Petrusewicz J., Turowski M., Damasiewicz B. Synthesis, structure and antiaggregatory effects of some α-hydroxy analogues of 2-aryliminoimidazolines in human platelets. Eur. J. Pharm. Sci. 4:1996;85.
10. Saczewski F., Debowski T., Petrusewicz J., Trzeciak H., Krzystanek E., Krzystanek M., Gdaniec M., Nowakowska E. Synthesis, structure and biological activities of some N-(4,5-dihydro-1H-imidazol-2-yl)-1,3-dihydrobenzimidazole derivatives. Arch. Pharm. Pharm. Med. Chem. 331:1998;241.
11. A.R. Katritzky, F. Saczewski, Preparation of N-(4,5-dihydroimidazol-2-yl)azoles by aliphatic assisted reactions of 2-chloro-4,5-dihydroimidazole with various azoles, Synthesis (1990) 561.
12. Lutz R.P. Catalysis of the cope and claisen rearrangements. Chem. Rev. 84:1984;205.
13. S. Blechert, The hetero-Cope rearrangement in organic synthesis, Synthesis 71 (1989).
14. M. Toyota, K. Fukumoto, Tandem Michael addition-[3.3]sigmatropic rearrangement processes. Part 2. Construction of cyclopropa[3,4]pyrrolo[3,2-e]indol-4-one (CPI) unit of antitumor antibiotic CC-1065, J. Chem. Soc. Perkin Trans. I 547 (1992).
15. Hwu J.R., Patel H.V., Lin R.J., Gray M.O. Novel methods for the synthesis of functionalized indoles from arylhydroxylamines and activated acetylenes. J. Org. Chem. 59:1994;1577.
16. Saczewski F., Debowski T., Gdaniec M., Gdaniec Z. Reactions of N-aryl-N-(4,5-dihydro-1H-imidazol-2-yl)hydroxylamines with electron-deficient acetylenes. Synthesis and structure of novel heterocyclic ketene aminals. J. Org. Chem. 61:1996;5425.
17. Allen F.H., Kennard O., Taylor R. Chem. Des. Automat. News. 8:1993;131.
18. Full geometry optimization was performed using semiempirical AM1 method as implemented into HYPERCHEM program, version 3.0, Hypercube, Inc.
19. Born G.V.R. Aggregation of blood platelets by adenosin diphosphate and its reversal. Nature. 194:1962;927.
20. Ding Y.A., McIntyre D.E., Keynon C.I., Semple P.F. Potentiation of adrenaline-induced platelet aggregation by angiotensin. Thromb. Haemostasis. 54:1985;717.
21. Petrusewicz J., Lasslo A., Carter-Burks G., Gollamudi R., Dillingham E.O., Bond S.E. Relationships between chemical structure and inhibition of epinephrine-induced human blood platelet aggregation. Biochem. Biophys. Acta. 983:1989;161.
22. G.M. Sheldrick, SHELXS-86. Program for the solution of crystal structures. University Of Göttingen, Germany, 1986.
23. G.M. Sheldrick, SHELXL-93. Program for the Refinement of Crystal Structures, University of Göttingen, Germany, 1993.
24. 2-adrenoreceptor status. Thromb. Res. 49:1988;531.
25. Petrusewicz J., Kaliszan R. Human blood platelet α-adrenoreceptor in view of the effects of various imidazol(in)e drugs on aggregation. Gen. Pharmacol. 22:1991;819.